Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh Buys 3,360 Shares

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh bought 3,360 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were purchased at an average price of $7.68 per share, with a total value of $25,804.80. Following the acquisition, the chief executive officer now directly owns 210,852 shares in the company, valued at approximately $1,619,343.36. This trade represents a 1.62 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daxor Stock Up 4.0 %

NASDAQ:DXR traded up $0.31 during trading hours on Tuesday, hitting $8.06. The stock had a trading volume of 1,651 shares, compared to its average volume of 6,167. The business has a 50 day simple moving average of $7.75 and a two-hundred day simple moving average of $8.50. Daxor Co. has a 1-year low of $6.55 and a 1-year high of $10.00.

Hedge Funds Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC increased its stake in shares of Daxor Co. (NASDAQ:DXR) by 87.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,821 shares of the company’s stock after buying an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Daxor worth $214,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.